Immunic, Inc.

Immunic did not report product revenue on the call. Q3 2024 net loss was approximately $24.4 million, or $0.24 per basic and diluted share, versus a net loss of approximately $22.8 million, or $0.51 per share, in Q3 2023. Nine-month 2024 net loss was approximately $75.3 million, or $0.75 per share, versus approximately $72 million, or $1.63 per share, in the prior-year period. R&D expense was $21.4 million in Q3 2024 versus $19.8 million a year ago, and $58.4 million for the first nine months of 2024 versus $63.9 million last year. G&A expense was $4.4 million in Q3 2024 versus $3.8 million a year ago, and $14 million for nine months versus $11.9 million. Cash and cash equivalents were $59.1 million at September 30, 2024, which management said should fund operations into Q3 2025. Guidance-wise, the company expects CALLIPER topline data in April 2025, expects to complete the first ENSURE trial in Q2 2026 and the second in 2H 2026, and is preparing for Phase 2 testing of IMU-856 while exploring separate funding options for that asset.

Daniel Vitt framed the quarter around clinical and organizational progress, including added leadership, a strengthened board, and higher visibility for vidofludimus calcium at the MS R&D day and ECTRIMS. He repeatedly emphasized the drug’s dual mode of action, calling out neuroprotective Nurr1 activation plus anti-inflammatory DHODH inhibition, and said the company believes it could serve both relapsing and progressive MS. His tone was optimistic but still data-dependent, with emphasis on upcoming milestones rather than commercialization claims.

Glenn Whaley focused on the balance sheet and quarterly spending trends. He said cash and cash equivalents were $59.1 million at quarter-end and expected to fund operations into the third quarter of 2025. He also broke down Q3 2024 R&D expense of $21.4 million, G&A expense of $4.4 million, interest income of $0.8 million, other income of $600,000, and a Q3 net loss of $24.4 million; for nine months, R&D was $58.4 million, G&A was $14 million, interest income was $3 million, other income was negative $1.1 million, and net loss was $75.3 million. He attributed higher R&D in the quarter mainly to external clinical trial spending, partly offset by deprioritization of izumerogant, and noted the $4.8 million non-cash charge from tranche rights related to the January 2024 private placement.

Analysts focused heavily on CALLIPER: management said the April 2025 readout should include detailed data across the overall population and subforms, including confirmed disability worsening, NfL, GFAB, and brain atrophy. On post-COVID fatigue data, Daniel Vitt said the investigator-sponsored study is not under Immunic’s control, so he could not guide on timing, but he said the overlap of fatigue and EBV biology could be scientifically meaningful; he also said any post-COVID subgroup analysis in ENSURE or CALLIPER is not predefined, though it could be extracted later if relevant. On efficacy expectations in CALLIPER, Vitt said there is no hard hazard-ratio bar, but he suggested KOLs viewed about a 15% disability-protection benefit as meaningful and 20% as a clear signal, and he said accelerated approval could be discussed depending on the data. When asked about partnering, Jason Tardio said Immunic is talking to nearly every company with MS or neuroscience interest, and that interest has risen after recent BTK inhibitor failures, but he gave no specifics.